Current status of transition medicine for 21-hydroxylase deficiency in Japan: from the perspective of pediatric endocrinologists

MLA

Akari Nakamura-Utsunomiya, et al. “Current Status of Transition Medicine for 21-Hydroxylase Deficiency in Japan: From the Perspective of Pediatric Endocrinologists.” Endocrine Journal, vol. 69, Jan. 2022, pp. 75–83. EBSCOhost, https://doi.org/10.1507/endocrj.ej21-0292.

APA

Akari Nakamura-Utsunomiya, Yukihiro Hasegawa, Kei Takasawa, Tomohiro Ishii, Tomonobu Hasegawa, Toshihiro Tajima, Naoko Amano, & Shinobu Ida. (2022). Current status of transition medicine for 21-hydroxylase deficiency in Japan: from the perspective of pediatric endocrinologists. Endocrine Journal, 69, 75–83. https://doi.org/10.1507/endocrj.ej21-0292

Chicago

Akari Nakamura-Utsunomiya, Yukihiro Hasegawa, Kei Takasawa, Tomohiro Ishii, Tomonobu Hasegawa, Toshihiro Tajima, Naoko Amano, and Shinobu Ida. 2022. “Current Status of Transition Medicine for 21-Hydroxylase Deficiency in Japan: From the Perspective of Pediatric Endocrinologists.” Endocrine Journal 69 (January): 75–83. doi:10.1507/endocrj.ej21-0292.